Erlotinib can halt adenine induced nephrotoxicity in mice through modulating ERK1/2, STAT3, p53 and apoptotic...

Area of Science:

• Nephrology
• Pharmacology
• Molecular Biology

Background:

• Renal fibrosis is a critical factor in chronic kidney disease (CKD) progression.
• Understanding therapeutic targets to inhibit renal fibrosis is crucial for CKD management.

Purpose of the Study:

• To investigate the efficacy of erlotinib, a receptor tyrosine kinase inhibitor, in mitigating renal fibrosis.
• To explore the underlying mechanisms of erlotinib's action on renal fibrosis, including its antioxidant and anti-apoptotic effects.

Main Methods:

• A mouse model of renal fibrosis was induced using adenine.
• Mice were treated with erlotinib, adenine, or a combination of both.
• Kidney function markers (serum creatinine, urea, uric acid), oxidative stress biomarkers (malondialdehyde, reduced glutathione, catalase), and molecular markers (Bcl-2, p53, TGF-β1, p-ERK1/2, p-STAT3) were assessed.
• Histopathological evaluation of tubular injury and renal fibrosis was performed.

Main Results:

• Erlotinib treatment significantly improved kidney function by reducing serum creatinine, urea, and uric acid levels.
• Concurrent administration of erlotinib and adenine decreased malondialdehyde and increased reduced glutathione and catalase levels, indicating antioxidant effects.
• Erlotinib markedly reduced renal fibrosis and tubular injury, decreasing levels of TGF-β1, p-ERK1/2, and p-STAT3.
• Erlotinib upregulated Bcl-2 expression and downregulated p53 expression, suggesting anti-apoptotic activity.

Conclusions:

• Erlotinib effectively attenuates the development and progression of renal fibrosis.
• The therapeutic effects of erlotinib are mediated through anti-fibrotic, antioxidant, and anti-apoptotic pathways.
• Erlotinib shows potential as a therapeutic agent for managing chronic kidney disease characterized by renal fibrosis.